Literature DB >> 20445581

Signed outside: a surface marker system for transgenic cytoplasmic proteins.

V Wohlgensinger1, R Seger, M D Ryan, J Reichenbach, U Siler.   

Abstract

Chronic granulomatous disease is a primary immunodeficiency, comprising five molecular defects, characterized by an impaired respiratory burst activity of myeloid cells. We are currently developing a gene therapy vector for the p47phox-deficient form of chronic granulomatous disease. Classic intracellular immunostaining of the cytoplasmic p47phox transgene product, however, interferes with respiratory burst activity. In this study we report a new system for measuring p47phox expression: A single open reading frame encoding the surface marker protein ΔLNGFR (truncated low-affinity nerve growth factor receptor) linked to the p47phox transgene by the 2A oligopeptide coexpression technology. Translation generates two discrete products: p47phox localizing to the cytoplasm and 'ΔLNGFR-2A' localizing to the cell surface. Six weeks after transplantation of transduced autologous hematopoietic stem cells into p47-/- mice, the intracellular p47phox fluorescence-activated cell sorting (FACS) signal intensities corresponded to surface ΔLNGFR staining in monocytes, B cells, T cells and Sca I+ bone marrow cells in vivo. The p47phox cleavage product restored nicotinamide adenine dinucleotide phosphate-oxidase activity in granulocytes differentiated from transduced p47phox-/- murine hematopoietic stem cells ex vivo, in murine granulocytes/monocytes in vivo, and in transduced human monocyte derived macrophages from p47phox-deficient chronic granulomatous disease patients. In conclusion, this new marker system allows highly efficient, indirect detection of cytoplasmic transgene products by FACS surface staining.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445581     DOI: 10.1038/gt.2010.73

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  3 in total

1.  Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.

Authors:  Christian Brendel; Walther Hänseler; Vital Wohlgensinger; Matteo Bianchi; Serap Tokmak; Linping Chen-Wichmann; Elena Kuzmenko; Nikola Cesarovic; Flora Nicholls; Janine Reichenbach; Reinhard Seger; Manuel Grez; Ulrich Siler
Journal:  Hum Gene Ther Methods       Date:  2013-05-02       Impact factor: 2.396

2.  Transcytosis in the blood-cerebrospinal fluid barrier of the mouse brain with an engineered receptor/ligand system.

Authors:  Héctor R Méndez-Gómez; Albert Galera-Prat; Craig Meyers; Weijun Chen; Jasbir Singh; Mariano Carrión-Vázquez; Nicholas Muzyczka
Journal:  Mol Ther Methods Clin Dev       Date:  2015-10-07       Impact factor: 6.698

3.  CRISPR/Cas9-generated p47phox-deficient cell line for Chronic Granulomatous Disease gene therapy vector development.

Authors:  Dominik Wrona; Ulrich Siler; Janine Reichenbach
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.